Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224264 | 0.86 | MAP4K4 (0.42) | CYP8B1 | |
| SCHEMBL1224605 | 0.80 | SIGMAR1 (0.45) | KCNH2SLC2A1PIK3CA | |
| SCHEMBL14539419 | 0.78 | KCNH2 (0.38) | KCNH2SLC2A1 | |
| SCHEMBL1222813 | 0.77 | KCNH2 (0.40) | KCNH2SLC2A1 | |
| SCHEMBL21061155 | 0.72 | PKLR (0.44) | PKLR | |
| SCHEMBL3662100 | 0.72 | LMNA (0.43) | KCNH2 | |
| SCHEMBL3960269 | 0.68 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL5309028 | 0.68 | LMNA (0.43) | KCNH2 | |
| SCHEMBL2790975 | 0.68 | ALDH1A1 (0.40) | KCNH2 | |
| Oxalic Acid SCHEMBL5255846 | 0.67 | POLB (0.40) | CYP8B1KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |